Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
This is a prospective, multicenter, single-arm clinical study on the treatment of newly diagnosed diffuse large B-cell lymphoma with high-risk of CNS relapse defined by CNS-IPI using Orelabrutinib in combination with R-CDOP regimen.
- EligibilityCriteria: Inclusion Criteria:  Age ≥18 years old; ECOG score 0-3; Histologically confirmed diffuse large B-cell lymphoma, including DLBCL and transformed DLBCL; CNS-IPI≥4 points Previously untreated participants with CD20-positive DLBCL,; Heart, liver, and kidney function: creatinine < 2 times the normal upper limit (ULN); ALT (alanine aminotransferase)/AST (Aspartate Aminotransferase) < 2.5ULN; Total bilirubin < 2ULN; Cardiac ejection fraction (EF) ≥50%. At least one measurable lesion. Have the sufficient understanding ability and voluntarily sign informed consent.  Exclusion Criteria:  Patients with evidence of CNS involvement ; Clinically significant active cardiovascular disease, such as uncontrolled arrhythmia, uncontrolled hypertension, congestive heart failure, any grade 3 or 4 heart disease as determined by the New York Heart Association (NYHA) functional scale, or a history of myocardial infarction within 6 months before screening; Human immunodeficiency virus (HIV) infection; Pregnant or lactating women; Other tumors that require treatment; Uncontrolled active infection; The HBV DNA copy number of active hepatitis after antiviral treatment can not be controlled within 2×103/ml. unable to understand and follow the research protocol or unable to sign the informed consent. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult